The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8

COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Argos Therapeutics Inc. Common 040221103 83 826,153 SH   DFND 1 0 826,153 0
Argos Therapeutics Inc. Common 040221103 26 256,030 SH Call DFND 1 0 256,030 0
Proteon Therapeutics Inc. Common 74371L109 3,135 1,607,807 SH   DFND 1 0 1,607,807 0
Protagonist Therapeutics, Inc. Common 74366E102 7,724 750,632 SH   DFND 1 0 750,632 0
Jounce Therapeutics, Inc. Common 481116101 3,673 565,063 SH   DFND 1 0 565,063 0
Allena Pharmaceuticals Common 018119107 9,376 873,031 SH   DFND 1 0 873,031 0
Neon Therapeutics Inc. Common 64050Y100 5,027 588,611 SH   DFND 1 0 588,611 0